Eugit Therapeutics
YC S22 · Active · Enabling Tissue Targeting of Therapies
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
 SynsoryBioShared: diseased tissue, oncology, synthetic biologyActiveOther | Other | Active | YCW24 |
 AlixiaShared: oncology, therapeutics, biotechnologyActiveOther | Other | Active | YCW22 |
 Modulari-TShared: cell therapy, oncology, synthetic biologyActiveOther | Other | Active | YCW23 |
 SFA TherapeuticsShared: inflammatory disease, clinical trial, biotechnologyActiveAI | AI | Active | YCS21 |
 Granza BioShared: oncology, synthetic biology, therapeuticsActiveOther | Other | Active | YCW24 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
 Sensible BiotechnologiesShared: synthetic biology, therapeutics, biotechnologyActiveOther | Other | Active | YCS21 |
 ExogeneShared: cell receptor, biotechnologyNot statedAI | AI | Not stated | EF2020 |
 Kopra BioShared: oncology, synthetic biology, therapeuticsActiveOther | Other | Active | YCS24 |
 GEn1E LifesciencesShared: inflammatory disease, therapy, clinicalActiveAI | AI | Active | YCS19 |
 Dorian TherapeuticsShared: therapeutics, tissue, diseaseAcquiredOther | Other | Acquired | YCS18 |
Also from S22
All of S22
About Eugit Therapeutics
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
- YC batch
- S22 · Summer 2022
- Status, per YC
- Active
- Category
- Other
- Team size
- 2
- Location
- San Francisco, CA, USA; South San Francisco, CA, USA
- Checked
- 35m ago
YC tags: Cell Therapy, Synthetic Biology, Therapeutics, Oncology, Biotechnology
Eugit Therapeutics: questions
Which YC batch was Eugit Therapeutics in?
Eugit Therapeutics was in Y Combinator's Summer 2022 batch (S22).
Is Eugit Therapeutics still active?
Y Combinator lists Eugit Therapeutics as active.
Where is Eugit Therapeutics based?
Eugit Therapeutics lists San Francisco, CA, USA; South San Francisco, CA, USA as its location on YC's directory.
Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.